On November 22, 2017 the Federal Court issued a judgment granting Apotex's motion under s. 6(5)(b) of the PMNOC Regulations: Bristol-Myers Squibb et al v Apotex Inc et al, 2017 FC 1061. As a result, the Court granted an order dismissing the underlying application in respect of Apotex's proposed generic aripiprazole product (Bristol-Myers Squibb and Otsuka's ABILIFY). The decision is under appeal.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
